GlyNAC: Glycine + NAC Explained

GlyNAC is the combination of glycine and N-acetylcysteine (NAC). It is not a new molecule, and “GlyNAC” does not automatically mean one specific branded product. The research idea is simple: glutathione synthesis requires both glycine and cysteine, and NAC can supply cysteine.

The human evidence is promising enough to justify serious attention, but it is much smaller than the marketing language often suggests. The key trials differ in size, duration, population and outcome—and one of the larger randomized studies had a negative overall primary glutathione result.

For NAC alone, start with our NAC supplement guide. For outcome-by-outcome analysis, see GlyNAC benefits.

GlyNAC at a glance

Question	Current answer
What is GlyNAC?	Glycine + N-acetylcysteine taken together.
Why combine them?	They supply two substrates used to synthesize glutathione: glycine and cysteine.
Is there human research?	Yes, including randomized trials and small pilot studies in older adults.
Does it always raise glutathione?	No. A 114-person two-week randomized trial did not increase circulating glutathione overall versus placebo.
Is it proven anti-aging?	No. Trials have measured biomarkers and functional outcomes, not human lifespan extension or reversal of aging.
Is more always better?	No. Dose-response and long-term outcome data remain incomplete.

Why glycine plus NAC?

Glutathione is a tripeptide made from glutamate, cysteine and glycine. NAC is widely used as a cysteine donor. GlyNAC adds glycine so that two of the three glutathione building blocks are supplied together.

This does not mean glutathione production is controlled only by those two ingredients. Synthesis is regulated, tissue-specific and influenced by baseline nutritional and redox status. That nuance becomes important when we look at the trials.

Read NAC and glutathione for the underlying pathway.

The 16-week randomized older-adult trial

The most cited GlyNAC efficacy trial randomized 24 older adults to GlyNAC or an isonitrogenous alanine placebo for 16 weeks; 12 younger adults served as a reference group and received GlyNAC for two weeks.

The randomized trial reported improvements across multiple measures including glutathione deficiency, oxidative stress, mitochondrial function, inflammation, insulin resistance, endothelial function and physical function.

Those results are genuinely interesting. The limitations are equally important: only 12 older adults received GlyNAC and 12 received placebo, it was a single-center trial, and many endpoints were tested. It is evidence—not final proof.

The 114-person dose-ranging trial changes the story

A separate randomized controlled study enrolled 114 healthy older adults with a mean age around 65 and tested three GlyNAC doses for two weeks: 2.4, 4.8 or 7.2 g/day total, using a 1:1 glycine-to-NAC ratio.

This larger dose-ranging trial is essential because its overall result was more restrained than many GlyNAC summaries imply. GlyNAC did not increase circulating glutathione versus placebo overall, the study's primary endpoint. Exploratory stratification suggested that participants with higher oxidative stress and lower glutathione status were more likely to respond.

The trial lasted only two weeks, so it cannot rule in or rule out longer-term functional effects. It also had important industry ties: multiple authors were affiliated with Nestlé Research or Nestlé Health Science, which has commercial interests involving glycine and NAC. That does not invalidate the trial, but it belongs in the interpretation.

The earlier pilot study

Much of the excitement around GlyNAC began with a 24-week pilot study in only eight older adults, compared with eight younger adults. A broad range of biochemical and functional measures improved during supplementation and some regressed after withdrawal.

Because the older group was extremely small and open-label, the study was hypothesis-generating. Its value was showing a signal worth testing—not establishing an anti-aging treatment.

What about people living with HIV?

An earlier 12-week open-label pilot in older adults with HIV also reported improvements across several glutathione, mitochondrial, metabolic and functional measures.

Again, the sample was very small and the population was disease-specific. It should not be generalized directly to healthy middle-aged or older adults.

Is GlyNAC an anti-aging supplement?

That description goes beyond the evidence.

The trials have measured features associated with aging—oxidative stress, mitochondrial function, inflammation, insulin resistance, endothelial function, strength, walking performance and molecular markers. They have not shown that GlyNAC extends human lifespan, reduces age-related mortality, or “reverses aging” in a validated clinical sense.

A narrative review of GlyNAC and healthy aging explains the mechanistic hypothesis, but a review cannot make the underlying small trials larger or more definitive.

A larger trial is now underway

The evidence base is moving forward. The U.S. National Institute on Aging is funding a randomized clinical trial designed to enroll 150 typical older adults, compare two GlyNAC doses over 24 weeks, and examine glutathione, oxidative stress, mitochondrial function, inflammation, insulin resistance, endothelial function, physical function, body composition and quality of life. The federal award period began in February 2026 and runs through 2031.

The NIH award record shows why this next study matters: it directly addresses the small samples and dose uncertainty in the current literature.

What doses have been studied?

GlyNAC dosing is not standardized across the literature. The 114-person study tested 2.4, 4.8 and 7.2 g/day total in a 1:1 ratio. Other trials have used different regimens and longer durations.

That is why “the GlyNAC dose” is not one settled number. We keep the protocol details in the dedicated GlyNAC dosage guide.

Can you make GlyNAC by taking glycine and NAC separately?

Conceptually, GlyNAC research is about taking glycine and NAC together rather than a chemically bonded compound. But reproducing a trial means matching the actual ingredients, dose ratio, duration and population—not simply adding arbitrary amounts of two supplements to a stack.

Bottom line

GlyNAC is one of the more interesting emerging combinations in healthy-aging research, but it is still emerging. A small 16-week randomized trial was broadly positive; a larger two-week dose-ranging trial was more mixed and missed its overall circulating-glutathione endpoint. Larger trials should tell us whether the early signals translate into reliable, clinically meaningful benefits.